Reversal of Dabigatran Anticoagulant Effect With Idarucizumab

Inclusion criteria: * Group A (Bleeding patients) * Overt bleeding judged by the physician to require a reversal agent * Currently taking dabigatran etexilate * At least 18 years of age * Written informed consent * Group B (Patients who are taking dabigatran who may not be bleeding, but do require an emergency surgery or procedure for a condition other than bleeding * Condition requiring emergency surgery or invasive procedure where adequate hemostasis is required. Emergency is defined as within the following 8 hours. * Current treatment with dabigatran * At least 18 years of age * Written Informed consent. Exclusion criteria: * Group A (Bleeding Patients) * Patients with minor bleeds (epistaxis, hematuria) who can be managed with standard supportive care. * Patients with no clinical signs of bleeding * Contraindications to study medication including known hypersensitivity to the drug or its excipients. * Group B (Patients who require emergency surgery or procedure) * A surgery or procedure which is elective or where the risk of uncontrolled or unmanageable bleeding is low. * Contraindications to study medication including known hypersensitivity to the drug or its excipients (subjects with hereditary fructose intolerance may react to sorbitol).